Sandra Prior

I have over 15 years’ experience in applied immunology and the development of in vitro cell-based bioassays and immunoassays for both biotherapeutics and vaccines.
I work as a Senior Scientist at the National Institute for Biological Standards and Control (NIBSC, UK) since 2015 where I investigate structure-function in relation to the safety and efficacy of monoclonal antibody and develop WHO bioassay standards for therapeutic monoclonal antibodies. I am a member of the European Directorate for the Quality of Medicines and HealthCare (EDQM) monoclonal antibody expert committee and the Official Medicines Control Laboratory (OMCL) monoclonal antibody testing group. Recently I also contribute to the investigation of immunological aspects of SARS-Cov2 infection.
Formerly, I received my Ph.D. from the University of Navarra (Pamplona, Spain) working in collaboration with the Federal Institute for Technology (ETH, Zurich, Switzerland) on the development of drug delivery systems for the treatment of brucellosis. Later I worked as a post-doctoral scientist at NIBSC evaluating safety and protective mechanisms of bacterial vaccines. In 2010, I joined Lonza Biologics (Cambridge, UK) where I worked on bioassay development as well as preclinical in vitro immunogenicity assessment of a wide portfolio of biological products and targets leading customer-orientated and technical development projects.